Navigation Links
Acquisitions, Clinical Trial Results, Date Extensions and Financial Results - Research Report on Endo, Astex, Auxilium, Accuray, and BioScrip
Date:9/2/2013

NEW YORK, September 2, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Endo Health Solutions Inc. (NASDAQ: ENDP), Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), Accuray Incorporated (NASDAQ: ARAY), and BioScrip Inc. (NASDAQ: BIOS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Endo Health Solutions Inc. Research Report

On August 28, 2013, Endo Health Solutions Inc. (Endo) announced that its subsidiary, Qualitest, has reached a definitive agreement to acquire Boca Pharmacal, a privately held specialty generics company, for $225 million in cash. According to Endo, the acquisition is expected to generate EBITDA of approximately $50 million in full-year 2013 on a standalone basis. Rajiv de Silva, President and CEO of Endo, said, "The acquisition is aligned with our current generics footprint and will meaningfully accelerate the growth of Qualitest in 2014. I believe that the revenue and earnings contribution of this transaction, combined with the unique commercial portfolio and strong pipeline of ANDAs, make this an ideal fit." Endo expects the deal to close before the end of 2013, subject to standard regulatory requirements. The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at
'/>"/>

SOURCE Investors' Reports
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Verum.de Exhibits at Outsourcing in Clinical Trials Southern California
2. Leading the Site CTMS Market: Clinical Conductor CTMS Reaches 1,600 Sites
3. Clinovo Sponsors Outsourcing in Clinical Trials Southern California Conference 2013, in La Jolla (CA), September 24-25
4. Mytrus Electronic Informed Consent System Selected for 2013 Product Leadership Award in Clinical Trials
5. In Vitro Safety Screening for Clinical Liabilities, New Life Science Webinar hosted by Xtalks
6. ACRES Launches Global Clinical Research Network Technology Platform
7. Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients
8. Indiana University Contracts with Virtify for Clinical Trial Disclosure Solutions
9. LabAnswer and OpGen Implement the STARLIMS Cloud Platform to Support OpGenā€™s CLIA Certified Clinical Services Laboratory in Under Four Months
10. Study Scavenger and CenterWatch Partner to Improve Patient Recruitment, Enrollment and Mobile Access to Clinical Trials with New Study Scavenger Smartphone App
11. MD Biosciences Offers IL-23-Induced Psoriasis-Like Preclinical Model for Skin Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... 35 th Annual Canaccord|Genuity Growth Conference in ... Chairman and CEO, William C. Taylor , President ...
(Date:8/3/2015)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), the ... diseases, today announced that it will host its First ... Thursday, August 13, 2015 at 4:30 p.m. Eastern Time. ... release of fiscal 2016 first quarter results.  A recorded ... hours after the call at the Investor Relations portion ...
(Date:8/3/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... development of autologous cell therapies, announced today that RepliCel,s CEO, ... conference held in Minneapolis, Minnesota on ... presentation will highlight RepliCel,s 18-month milestones including CE Mark for ... , clinical data from both RCT-01 (tendon) and RCS-01 ...
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... Electronic health record systems generally are perceived to have ... more clinics consider moving from paper charts to EHR ... barriers to entry. , ,The evolution of systems for ... robust data security has prompted more hospitals and ...
... - Just six weeks after taking the helm at ... to pursue opportunities in the private sector, the organization announced. ... has served as general counsel to WiCell's parent, the ... high-tech and biotechnology industries. , ,Donley, who joined WARF in ...
... An education research team at the University of Wisconsin-Madison ... to study the impact of digital media on youth ... investment will support 24 national studies of different aspects of ... , ,"What MacArthur is actually trying to do, with this ...
Cached Biology Technology:GE Healthcare launches hybrid electronic record 2Donley resigns as WiCell director 2UW gets $3M to explore educational gaming 2UW gets $3M to explore educational gaming 3
(Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... a form of breast cancer known as estrogen receptor positive ... the treatment and prevention of recurring breast cancer. Currently, ... dose is prescribed for every patient. New research at ... patient-specific genetic factors, lack of exposure to vitamin D during ...
... DNA code for a complex region of the human genome ... Fraser University, chart new territory in immunity research. , They ... how well they operate and, potentially, what they fight off, ... drugs, treatments and vaccinations are designed to treat whole populations ...
... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... study of seven missense variants of the BRCA1 gene ... to the risk of suffering breast or ovarian cancer. ... PLoS One The classification of these three ...
Cached Biology News:Cold winters freezing out breast cancer treatment 2Scientists find ethnicity linked to antibodies 2Identified as responsible for breast and ovarian hereditary cancer 3 mutations at BRCA1 gene 2
...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
Biology Products: